1. Home
  2. MRKR vs BFRI Comparison

MRKR vs BFRI Comparison

Compare MRKR & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

BUY

Current Price

$0.95

Market Cap

19.5M

Sector

Health Care

ML Signal

BUY

Logo Biofrontera Inc.

BFRI

Biofrontera Inc.

HOLD

Current Price

$0.92

Market Cap

16.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRKR
BFRI
Founded
1999
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
16.3M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
MRKR
BFRI
Price
$0.95
$0.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
★ $7.87
$6.00
AVG Volume (30 Days)
60.0K
★ 631.5K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
33.61
★ 67.70
EPS
★ N/A
N/A
Revenue
N/A
★ $41,705,000.00
Revenue This Year
$19.61
$10.65
Revenue Next Year
$375.85
$15.88
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 11.75
52 Week Low
$0.84
$0.57
52 Week High
$2.46
$1.66

Technical Indicators

Market Signals
Indicator
MRKR
BFRI
Relative Strength Index (RSI) 31.50 30.31
Support Level N/A $0.78
Resistance Level $1.31 $0.98
Average True Range (ATR) 0.07 0.08
MACD -0.02 -0.03
Stochastic Oscillator 5.58 10.98

Price Performance

Historical Comparison
MRKR
BFRI

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

Share on Social Networks: